4-(Imidazo[1,2-a]pyridin-3-yl): pyrimidine derivatives as anticancer agents.

doi:10.4155/ppa-2022-0033

Paper

4-(Imidazo[1,2-a]pyridin-3-yl): pyrimidine derivatives as anticancer agents.

Published Nov 10, 2022 · R. Al‐Horani

Pharmaceutical patent analyst

Q2 SJR score

1

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

A series of 4-(imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives are claimed as inhibitors of c-KIT and as potential treatments for cancer. Their chemical preparation and biological evaluation against imatinib-resistant tumor cells have been described. Several claimed molecules have excellent IC50 values in the nanomolar range. Several molecules were also selective against a wide panel of kinases. Few specific inhibitors have been found to have promising oral bioavailability and acceptable to excellent values regarding the inhibition of hERG channel. This class represents a new platform for developing new anticancer treatment against a wide range of c-KIT mutations and secondary mutations that may arise in gastrointestinal stromal tumor patients.

Study Snapshot

4-(imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives show potential as anticancer agents against a wide range of c-KIT mutations and secondary mutations in gastrointestinal stromal tumor patients.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

4-(Imidazo[1,2-a]pyridin-3-yl): pyrimidine derivatives as anticancer agents.

References

Citations